- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1992 (FDA)
- Why 3/10
- Proleukin is an already-approved, marketed drug with no pending regulatory decision or pivotal readout specific to it. There is no hard dated binary catalyst for this drug in the next ~12 months. The next major catalysts for IOVA stock relate to Amtagvi (lifileucel), the TIL-301 Phase 3 confirmatory trial readout and potential NSCLC label expansion, not to Proleukin. At ~17% of Iovance's product revenue, Proleukin is a modest, steady revenue contributor but not a share-price swing factor.
Proleukin is a steady, low-growth commercial asset for Iovance, providing ~$44M-60M in annual revenue (17% of total product sales). It functions largely as a support drug for Iovance's flagship TIL therapy Amtagvi. For IOVA investors, the stock's binary catalysts revolve around Amtagvi's label expansion (Phase 3 frontline melanoma, NSCLC), not Proleukin. Proleukin's main risk is gradual revenue erosion from newer engineered IL-2 competitors and potential biosimilar entry given its long-expired patents.
Price Chart
Executive Summary
Proleukin (aldesleukin) is an older, FDA-approved recombinant IL-2 immunotherapy for metastatic renal cell carcinoma and metastatic melanoma, first approved in 1992. Iovance Biotherapeutics (IOVA) acquired worldwide rights from Clinigen in January 2023 for £166.7M upfront. The drug generated ~$60.5M in revenue for Iovance in FY2024 and ~$44M in FY2025 (~17% of total product revenue). Proleukin is strategically important to Iovance because it's used in the conditioning regimen for its flagship TIL therapy Amtagvi (lifileucel). However, as an already-approved drug with no pending FDA decision or pivotal readout, Proleukin itself is not a binary catalyst stock driver. The IOVA thesis centers on Amtagvi's commercial ramp and label expansion, while Proleukin provides steady, modest supplemental revenue.
How It Works
Proleukin is a synthetic version of interleukin-2 (IL-2), a protein the body's immune system naturally produces. It works by stimulating the growth and activity of T cells and natural killer (NK) cells, key types of immune cells that attack cancer. It is given intravenously and essentially 'kick-starts' the immune system to fight tumors. However, it is known for severe side effects, most notably capillary leak syndrome (fluid leaking from blood vessels into tissues), which requires treatment in a hospital setting with careful monitoring.
Trial Status
FDA-approved since 1992 for metastatic renal cell carcinoma and metastatic melanoma. Iovance acquired worldwide rights in January 2023 and currently markets the drug commercially. Proleukin is used in the conditioning regimen for Iovance's Amtagvi (lifileucel) TIL therapy and also sold for other commercial/clinical uses. Orphan Drug Designation was granted for ALS in 2021 (by prior owner Clinigen), but Iovance has not disclosed active late-stage development in that indication.
The Two-Sided Case
Upcoming Catalysts
- Amtagvi (lifileucel) Phase 3 TILVANCE-301 confirmatory trial readout in frontline advanced melanoma (key IOVA catalyst, not Proleukin-specific)
- Potential FDA decision on Amtagvi label expansion into second-line non-small cell lung cancer (Fast Track granted)
- Iovance Q2 2026 earnings (early August 2026), Proleukin revenue trends as part of total product revenue
- Quarterly sales trajectory showing Proleukin's steady-state run rate as Amtagvi adoption grows
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report